Companies / Deuteroncology
Deuteroncology
Liege, Belgium
Deuteroncology is developing a deuterated MET kinase inhibitor as a potential targeted therapy for MET driven disease
Deuteroncology, based in Liege, Belgium, has 2 investors on file, among them Newton Biocapital and Noshaq. Its site was last checked 13 Nov 2026: site answers.
Investors
2 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital | |
| Portfolio page | Investor |
More from Newton Biocapital
13 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (100%).
See Newton Biocapital's full profile · Who invests alongside it
More from Noshaq
186 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (23%), AI & Machine Learning (19%), Industrial & Manufacturing (13%).
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Deuteroncology and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Newton Biocapital adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/deuteroncology.com/investors
# also
GET /v1/companies/deuteroncology.com
GET /v1/companies/deuteroncology.com/news